In contrast to the clinical development of other 11beta-HSD1 inhibitors, data on enzyme inhibition in liver and AT were assessed with BI 187004 already in the first-in-human trial in subjects with overweight or obesity, a population close to the target population of T2DM and obesity. This evidence concerns the gene HSD11B1 and type 2 diabetes mellitus.